Clinical Trial: A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) with MGMT promotor region unmethylated (China)

China, Nov. 2 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) with MGMT promotor region unmethylated'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135619

Registration Time: 2026/10/30

Type: Interventional study

Primary Sponsor: Cancer Center, Sun Yat-sen University (Sun Yat-sen University Cancer Center, Sun Yat-sen University Cancer Institute)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=347106

Published by HT Digital Content Services with permission from Heal...